Accumulation of 99mTc-HMPAO and 99mTc-ECD in rodent and human breast tumor cell lines in vitro

Annals of Nuclear Medicine

Volumn 11, Issue 2, 1997, Pages 95-99

  Ballinger, James R ^a   Duncan, Jill ^b   Hua, H A ^b   Ichise, Masanori ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b NONE

Author keywords

Retention mechanism; Technetium 99m ECD; Technetium 99m HMPAO; Tumor imaging

Indexed keywords

CYSTEINE ETHYL ESTER TC 99M; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; CYSTEINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; OXIME; TECHNETIUM COMPLEX; TECHNETIUM TC 99M BICISATE;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; DRUG ACCUMULATION; DRUG RETENTION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; BREAST TUMOR; CELL CULTURE; COMPARATIVE STUDY; FEMALE; METABOLISM; SCINTISCANNING; SPECIES DIFFERENCE;

ANIMALS; BREAST NEOPLASMS; CYSTEINE; FEMALE; HUMANS; ORGANOTECHNETIUM COMPOUNDS; OXIMES; RATS; SPECIES SPECIFICITY; TECHNETIUM TC 99M EXAMETAZIME; TUMOR CELLS, CULTURED;

EID: 0030612420     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03164816     Document Type: Article

References (22)

1. Neirinckx RD, Canning LR, Piper IM, Nowotnik DP, Pickett RD, Holmes RA, et al. Technetium-99m d,I-HM-PAO: A new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion. J Nucl Med 28: 191-202, 1987.
2. Vallabhajosula S, Zimmerman RE, Picard M, Stritzke P, Mena I, Hellman RS, et al. Technetium-99m ECD: A new brain imaging agent: In vivo kinetics and biodistribution studies in normal human subjects. J Nucl Med 30: 599-604, 1989.
3. Neirinckx RD, Burke JF, Harrison RC, Forster AM, Andersen AR, Lassen NA. The retention mechanism of technetium-99m-HM-PAO: Intracellular reaction with glutathione. J Cereb Blood Flow Metab 8: S4-S12, 1988.
4. Ballinger JR, Reid RH, Gulenchyn KY. Technetium-99m HM-PAO stereoisomers: Differences in interaction with glutathione. J Nucl Med 29: 1998-2000, 1988.
5. Jacquier-Sarlin MR, Polla BS, Slosman DO. Oxide-reductive state: The major determinant for cellular retention of technetium-99m-HMPAO. J Nucl Med 37: 1413-1416, 1996.
6. 99mTc-ECD). J Cereb Blood Flow Metab 14: S4-S11, 1994.
7. Jacquier-Sarlin MR, Polla BS, Slosman DO. Cellular basis of ECD brain retention. J Nucl Med 37: 1694-1697, 1996.
8. Inoue Y, Momose T, Watanabe T, Ohtake T, Nishikawa J, Sasaki Y. Properties of enzyme to catalyze Tc-99m ECD (abstr). J Nucl Med 37: 189P, 1996.
9. Grunwald F, Menzel C, Pietsch T, Pavics L, Hufnagel A, Biersack H-J. Increased technetium-99m-HMPAO uptake in Grade II astrocytoma. J Nucl Med 26: 804-806, 1995.
10. Suess E, Malessa S, Ungersbock K, Kitz P, Podreka I, Heimberger K, et al. Technetium-99m-d,1-hexamethylpropyleneamine oxime (HMPAO) uptake and glutathione content in brain tumors. J Nucl Med 32: 1675-1681, 1991.
11. Shih WJ, Coupal J, Magoun S. The biodistribution of technetium-99m-hexamethylpropylene amine oxime. Semin Nucl Med 24: 180-183, 1994.
12. Tanada S, Murase K, Inoue T, Sugawara Y, Miki H, Okumura A, et al. Comparison of kinetics in brain tumors between Tc-99m ECD and Tc-99m HMPAO with dynamic brain SPECT and compartmental model (abstr). J Nucl Med 33: 969-970, 1992.
13. Hirano T, Suzuki H, Higuchi T, Watanabe N, Oriuchi N, Shibazaki T, et al. Grade II astrocytoma visualized by technetium-99m-ECD SPECT. J Nucl Med 37: 273-275, 1996.
14. Schecter RL, Woo A, Duong M, Batist G. In vivo and in vitro mechanisms of drug resistance in a rat mammary carcinoma model. Cancer Res 51: 1434-1442, 1991.
15. Ballinger JR, Cowan DSM, Boxen I, Zhang ZM, Rauth AM. Effect of hypoxia on the accumulation of technetium-99m-glucarate and technetium-99m-gluconate by Chinese hamster ovary cells in vitro. J Nucl Med 34: 242-245, 1993.
16. 201Tl-thallous chloride in tumour cells: Role of P-glycoprotein. Quart J Nucl Med 39: 122-128, 1995.
17. 99mTc-Sestamibi as an agent for imaging P-glycoprotein-mediated multidrug resistance: In vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant. Nucl Med Commun 16: 253-257, 1995.
18. Suess E, Huck S, Reither H, Hortnagl H, Angelberger P. Uptake mechanism of technetium-99m-d,1-HMPAO in cell cultures of the dissociated postnatal rat cerebellum. J Nucl Med 33: 108-114, 1992.
19. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, Cowan KH. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 261: 15544-15549, 1986.
20. Ballinger JR, Wan Min Kee J, Rauth AM. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimi-dazole (BMS181321) as a marker of tumor hypoxia. J Nucl Med 37: 1023-1031, 1996.
21. m hexamethyl-propyleneamine oxime uptake in the tissues related to glutathione cellular content? Nucl Med Commun 10: 905-911, 1989.
22. Sasaki T, Toyama H, Oda K, Ogihara-Umeda I, Nishigori H, Senda M. Assessment of antioxidative ability in brain: Technetium-99m-meso-HMPAO as an imaging agent for glutathione localization. J Nucl Med 37: 1698-1701, 1996.